Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 15/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.39 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4619181 | 0.97 | ADRB3 (0.40) | ADRB3ADRB2ADRB1LIMK2 | |
| SCHEMBL4899119 | 0.94 | ADRB3 (0.42) | ADRB3ADRB2ADRB1ALDH1A1 | |
| SCHEMBL4900957 | 0.93 | ADRB3 (0.40) | ADRB3ADRB2ADRB1 | |
| Trifluoroacetic Acid SCHEMBL4616140 | 0.91 | ADRB3 (0.40) | ADRB3ADRB2ADRB1 | |
| SCHEMBL2201260 | 0.91 | ADRB3 (0.44) | ADRB3ADRB2ADRB1ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL4899089 | 0.91 | ADRB3 (0.40) | ADRB3ADRB2ADRB1 | |
| SCHEMBL2198134 | 0.90 | ADRB3 (0.41) | ADRB3ADRB2ADRB1POLB | |
| SCHEMBL2201023 | 0.90 | ADRB3 (0.41) | ADRB3ADRB2ADRB1POLB | |
| SCHEMBL2198132 | 0.90 | ADRB3 (0.41) | ADRB3ADRB2ADRB1POLB | |
| SCHEMBL2199633 | 0.90 | ADRB3 (0.42) | ADRB3ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080300290-A1 | Novel Beta-Agonists, Process for Their Preparation and Their Use as Medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-04 | — | — | US | claimed |
| US-20080300290-A1 | Novel Beta-Agonists, Process for Their Preparation and Their Use as Medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-04 | — | — | US | disclosed |
| US-20080300290-A1 | Novel Beta-Agonists, Process for Their Preparation and Their Use as Medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-04 | — | — | US | disclosed |
| US-20080300290-A1 | Novel Beta-Agonists, Process for Their Preparation and Their Use as Medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-04 | — | — | US | disclosed |
| WO-2007048840-A1 | NOVEL BETA-AGONISTS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300290-A1 | Novel Beta-Agonists, Process for Their Preparation and Their Use as Medicaments | ADRB1, ADRB3, ADRB2 | ADRB3 2/4885ADRB2 3/4885ADRB1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.